Al's Comment:

 This is a blog post from the chairman of the company that makes Val-083.   I think this trial will accrue patients faster than they predict as the early results are impressive and there really are not many competing trials looking for this patient population:  Patients with GBM who have failed Avastin and have unmethylated MGMT.  Worth looking at this trial.


Posted on: 02/04/2017

Optimism and Opportunity as we Initiate Clinical Trials for MGMT-unmethylated GBM Patients at MD Anderson

 

 

 


Click HERE to return to brain tumor news headlines.


Our privacy / cookie policy has changed.
Click HERE to read it!